1
|
Séguier D, Adams ES, Kotamarti S, D'Anniballe V, Michael ZD, Deivasigamani S, Olivier J, Villers A, Hoimes C, Polascik TJ. Intratumoural immunotherapy plus focal thermal ablation for localized prostate cancer. Nat Rev Urol 2024; 21:290-302. [PMID: 38114768 DOI: 10.1038/s41585-023-00834-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/02/2023] [Indexed: 12/21/2023]
Abstract
Major advances have been made in the use of immunotherapy for the treatment of solid tumours, including the use of intratumourally injected immunotherapy instead of systemically delivered immunotherapy. The success of immunotherapy in prostate cancer treatment has been limited to specific populations with advanced disease, which is thought to be a result of prostate cancer being an immunologically 'cold' cancer. Accordingly, combining intratumoural immunotherapy with other treatments that would increase the immunological heat of prostate cancer is of interest. Thermal ablation therapy is currently one of the main strategies used for the treatment of localized prostate cancer and it causes immunological activation against prostate tissue. The use of intratumoural immunotherapy as an adjunct to thermal ablation offers the potential to elicit a systemic and lasting adaptive immune response to cancer-specific antigens, leading to a synergistic effect of combination therapy. The combination of thermal ablation and immunotherapy is currently in the early stages of investigation for the treatment of multiple solid tumour types, and the potential for this combination therapy to also offer benefit to prostate cancer patients is exciting.
Collapse
Affiliation(s)
- Denis Séguier
- Department of Surgery, Division of Urology, Duke University Medical Center, Durham, North Carolina, 27710, USA.
- Department of Urology, Lille University, Lille, France.
- Cancer Heterogeneity Plasticity and Resistance to Therapies (CANTHER; UMR9020-U1277), Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, Lille, France.
| | - Eric S Adams
- Department of Surgery, Division of Urology, Duke University Medical Center, Durham, North Carolina, 27710, USA
| | - Srinath Kotamarti
- Department of Surgery, Division of Urology, Duke University Medical Center, Durham, North Carolina, 27710, USA
| | - Vincent D'Anniballe
- Department of Surgery, Division of Urology, Duke University Medical Center, Durham, North Carolina, 27710, USA
| | - Zoe D Michael
- Department of Surgery, Division of Urology, Duke University Medical Center, Durham, North Carolina, 27710, USA
| | - Sriram Deivasigamani
- Department of Surgery, Division of Urology, Duke University Medical Center, Durham, North Carolina, 27710, USA
| | - Jonathan Olivier
- Department of Urology, Lille University, Lille, France
- Cancer Heterogeneity Plasticity and Resistance to Therapies (CANTHER; UMR9020-U1277), Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, Lille, France
| | - Arnauld Villers
- Department of Urology, Lille University, Lille, France
- Cancer Heterogeneity Plasticity and Resistance to Therapies (CANTHER; UMR9020-U1277), Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, Lille, France
| | - Christopher Hoimes
- Department of Medicine, Division of Medical Oncology, Duke Cancer Institute, Duke University, Durham, North Carolina, 27708, USA
| | - Thomas J Polascik
- Department of Surgery, Division of Urology, Duke University Medical Center, Durham, North Carolina, 27710, USA
| |
Collapse
|
2
|
Gao L, Li Q, Zhang J, Huang Y, Deng L, Li C, Tai G, Ruan B. Local penetration of doxorubicin via intrahepatic implantation of PLGA based doxorubicin-loaded implants. Drug Deliv 2020; 26:1049-1057. [PMID: 31691602 PMCID: PMC6844384 DOI: 10.1080/10717544.2019.1676842] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
Doxorubicin (DOX) is widely used in the chemotherapy of a wide range of cancers. However, intravenous administration of DOX causes toxicity to most major organs which limits its clinical application. DOX-loaded drug delivery system could provide a continuous sustained-release of drugs and enables high drug concentrations at the target site, while reducing systemic toxicity. Additionally, local chemotherapy with DOX may be a promising approach for lowering post-surgical recurrence of cancer. In this study, the sustained-release DOX-loaded implants were prepared by melt-molding method. The implants were characterized with regards to drug content uniformity, micromorphology and drug release profiles. Furthermore, differential scanning calorimetry (DSC) and Fourier transform infrared spectroscopy (FTIR) analyses were carried out to investigate the drug-excipient compatibility. To determine the local penetration of DOX in liver, the minipigs received intrahepatic implantation of DOX-loaded implants by abdominal surgery. UPLC-MS/MS method was used to detect the concentration of DOX in liver tissues. Our results suggested that DOX-loaded implants delivered high doses of drug at the implantation site for a prolonged period and provided valuable information for the future clinical applications of the DOX-loaded implants.
Collapse
Affiliation(s)
- Li Gao
- School of Food and Biological Engineering, Hefei University of Technology, Hefei, People's Republic of China
| | - Qingshan Li
- School of Food and Biological Engineering, Hefei University of Technology, Hefei, People's Republic of China
| | - Jie Zhang
- School of Food and Biological Engineering, Hefei University of Technology, Hefei, People's Republic of China
| | - Yixin Huang
- School of Food and Biological Engineering, Hefei University of Technology, Hefei, People's Republic of China
| | - Lin Deng
- School of Food and Biological Engineering, Hefei University of Technology, Hefei, People's Republic of China
| | - Chenyang Li
- School of Food and Biological Engineering, Hefei University of Technology, Hefei, People's Republic of China
| | - Guangping Tai
- Key Lab of Biofabrication of Anhui Higher Education Institution Centre for Advanced Biofabrication, Hefei University, Hefei, People's Republic of China
| | - Banfeng Ruan
- Key Lab of Biofabrication of Anhui Higher Education Institution Centre for Advanced Biofabrication, Hefei University, Hefei, People's Republic of China
| |
Collapse
|
3
|
Controlling the burst release of doxorubicin from polymeric depots via adjusting hydrophobic/hydrophilic properties. J Drug Deliv Sci Technol 2018. [DOI: 10.1016/j.jddst.2018.06.001] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
4
|
Gupta S, Gupta PK, Dharanivasan G, Verma RS. Current prospects and challenges of nanomedicine delivery in prostate cancer therapy. Nanomedicine (Lond) 2017; 12:2675-2692. [DOI: 10.2217/nnm-2017-0236] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Management of prostate cancer is currently being pursued by systemic delivery of anticancer drugs, but it has drawbacks like nonspecific distribution, decreased bioavailability, coupled with adverse side effects. These problems have been resolved using nanomedicine-based anticancer drug delivery to improve the therapeutic index with higher drug dose and reduced nonspecific distribution. Targeting prostate tumor by delivering nanomedicine through locoregional route is more effective, than the systemic delivery, which can decrease systemic exposure of the therapeutics significantly. Therefore, in this article, we have reviewed the current prospects and challenges of prostate cancer therapy using nanomedicine, by providing a comprehensive description of advantages and limitations of the systemic route and locoregional route. Eventually, we have emphasized on the need for localized prostate cancer therapy developments using nanomedicines.
Collapse
Affiliation(s)
- Santosh Gupta
- Department of Biotechnology, Bhupat & Jyoti Mehta School of Biosciences, Indian Institute of Technology-Madras, Chennai-600036, Tamilnadu, India
| | - Piyush Kumar Gupta
- Department of Biotechnology, Bhupat & Jyoti Mehta School of Biosciences, Indian Institute of Technology-Madras, Chennai-600036, Tamilnadu, India
| | - Gunasekaren Dharanivasan
- Department of Biotechnology, Bhupat & Jyoti Mehta School of Biosciences, Indian Institute of Technology-Madras, Chennai-600036, Tamilnadu, India
| | - Rama Shanker Verma
- Department of Biotechnology, Bhupat & Jyoti Mehta School of Biosciences, Indian Institute of Technology-Madras, Chennai-600036, Tamilnadu, India
| |
Collapse
|
5
|
Belz JE, Kumar R, Baldwin P, Ojo NC, Leal AS, Royce DB, Zhang D, van de Ven AL, Liby KT, Sridhar S. Sustained Release Talazoparib Implants for Localized Treatment of BRCA1-deficient Breast Cancer. Am J Cancer Res 2017; 7:4340-4349. [PMID: 29158830 PMCID: PMC5695017 DOI: 10.7150/thno.18563] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2016] [Accepted: 06/17/2017] [Indexed: 01/17/2023] Open
Abstract
Talazoparib, a potent PARP inhibitor, has shown promising clinical and pre-clinical activity by inducing synthetic lethality in cancers with germline Brca1/2 mutations. Conventional oral delivery of Talazoparib is associated with significant off-target effects, therefore we sought to develop new delivery systems in the form of an implant loaded with Talazoparib for localized, slow and sustained release of the drug at the tumor site in Brca1-deficient breast cancer. Poly(lactic-co-glycolic acid) (PLGA) implants (0.8 mm diameter) loaded with subclinical dose (25 or 50 µg) Talazoparib were fabricated and characterized. In vitro studies with Brca1-deficient W780 and W0069 breast cancer cells were conducted to test sensitivity to PARP inhibition. The in vivo therapeutic efficacy of Talazoparib implants was assessed following a one-time intratumoral injection in Brca1Co/Co;MMTV-Cre;p53+/- mice and compared to drug-free implants and oral gavage. Immunohistochemistry studies were performed on tumor sections using PCNA and γ-H2AX staining. Sustained release of Talazoparib was observed over 28 days in vitro. Mice treated with Talazoparib implants showed statistically significant tumor growth inhibition compared to those receiving drug-free implants or free Talazoparib orally. Talazoparib implants were well-tolerated at both drug doses and resulted in less weight loss than oral gavage. PARP inhibition in mice treated with Talazoparib implants significantly increased double-stranded DNA damage and decreased tumor cell proliferation as shown by PCNA and γ-H2AX staining as compared to controls. These results demonstrate that localized and sustained delivery of Talazoparib via implants has potential to provide superior treatment outcomes at sub-clinical doses with minimal toxicity in patients with BRCA1 deficient tumors.
Collapse
|
6
|
Averin PS, Lopes de Gerenyu AV, Balabushevich NG. Polyelectrolyte micro- and nanoparticles with doxorubicin. ACTA ACUST UNITED AC 2016. [DOI: 10.3103/s0027131416020012] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
7
|
Sjögren E, Tammela TL, Lennernäs B, Taari K, Isotalo T, Malmsten LÅ, Axén N, Lennernäs H. Pharmacokinetics of an injectable modified-release 2-hydroxyflutamide formulation in the human prostate gland using a semiphysiologically based biopharmaceutical model. Mol Pharm 2014; 11:3097-111. [PMID: 25055161 DOI: 10.1021/mp5002813] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The local distribution of 2-hydroxyflutamide (2-HOF) in prostate tissue after a single intraprostatic injection of a novel parenteral modified-release (MR) formulation in patients with localized prostate cancer was estimated using a semiphysiologically based biopharmaceutical model. Plasma concentration-time profiles for 2-HOF were acquired from a phase II study in 24 patients and the dissolution of the MR formulation was investigated in vitro. Human physiological values and the specific physicochemical properties of 2-HOF were obtained from the literature or calculated via established algorithms. A compartmental modeling approach was adopted for tissue and blood in the prostate gland, where the compartments were modeled as a series of concentric spherical shells contouring the centrally positioned depot formulation. Discrete fluid connections between the blood compartments were described by the representative flow of blood, whereas the mass transport of drug from tissue to tissue and tissue to blood was described by a one-dimensional diffusion approximation. An empirical dissolution approach was adopted for the release of 2-HOF from the formulation. The model adequately described the plasma concentration-time profiles of 2-HOF. Predictive simulations indicated that the local tissue concentration of 2-HOF within a distance of 5 mm from the depot formulation was approximately 40 times higher than that of unbound 2-HOF in plasma. The simulations also indicated that spreading the formulation throughout the prostate gland would expose more of the gland and increase the overall release rate of 2-HOF from the given dose. The increased release rate would initially increase the tissue and plasma concentrations but would also reduce the terminal half-life of 2-HOF in plasma. Finally, an in vitro-in vivo correlation of the release of 2-HOF from the parenteral MR formulation was established. This study shows that intraprostatic 2-HOF concentrations are significantly higher than systemic plasma concentrations and that increased distribution of 2-HOF throughout the gland, using strategic imaging-guided administration, is possible. This novel parenteral MR formulation, thus, facilitates good pharmacological effect while minimizing the risk of side effects.
Collapse
Affiliation(s)
- Erik Sjögren
- Department of Pharmacy, Uppsala University , SE-751 23 Uppsala, Sweden
| | | | | | | | | | | | | | | |
Collapse
|
8
|
Sagnella SM, Duong H, MacMillan A, Boyer C, Whan R, McCarroll JA, Davis TP, Kavallaris M. Dextran-Based Doxorubicin Nanocarriers with Improved Tumor Penetration. Biomacromolecules 2013; 15:262-75. [DOI: 10.1021/bm401526d] [Citation(s) in RCA: 96] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Affiliation(s)
- Sharon M. Sagnella
- Children’s
Cancer Institute Australia, Lowy Cancer Research Centre, University of New South Wales, P.O. Box 81, Randwick, Australia
| | | | | | | | | | - Joshua A. McCarroll
- Children’s
Cancer Institute Australia, Lowy Cancer Research Centre, University of New South Wales, P.O. Box 81, Randwick, Australia
| | - Thomas P. Davis
- Monash
Institute of Pharmaceutical Sciences, Monash University, Parkville, Melbourne, Victoria, Australia
- Department
of Chemistry, University of Warwick, Coventry, United Kingdom
| | - Maria Kavallaris
- Children’s
Cancer Institute Australia, Lowy Cancer Research Centre, University of New South Wales, P.O. Box 81, Randwick, Australia
| |
Collapse
|
9
|
Duong HTT, Hughes F, Sagnella S, Kavallaris M, Macmillan A, Whan R, Hook J, Davis TP, Boyer C. Functionalizing Biodegradable Dextran Scaffolds Using Living Radical Polymerization: New Versatile Nanoparticles for the Delivery of Therapeutic Molecules. Mol Pharm 2012; 9:3046-61. [DOI: 10.1021/mp300144y] [Citation(s) in RCA: 60] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Affiliation(s)
- Hien T. T. Duong
- Australian
Centre for NanoMedicine‡Children’s Cancer Institute Australia, Lowy
Cancer Research Centre, §Biomedical Imaging Facility, Mark Wainwright
Analytical Centre, ∥Nuclear Magnetic Resonance Facility, Mark Wainwright Analytical Centre, The University of New South Wales, Sydney,
NSW 2052, Australia
| | - Felicity Hughes
- Australian
Centre for NanoMedicine‡Children’s Cancer Institute Australia, Lowy
Cancer Research Centre, §Biomedical Imaging Facility, Mark Wainwright
Analytical Centre, ∥Nuclear Magnetic Resonance Facility, Mark Wainwright Analytical Centre, The University of New South Wales, Sydney,
NSW 2052, Australia
| | - Sharon Sagnella
- Australian
Centre for NanoMedicine‡Children’s Cancer Institute Australia, Lowy
Cancer Research Centre, §Biomedical Imaging Facility, Mark Wainwright
Analytical Centre, ∥Nuclear Magnetic Resonance Facility, Mark Wainwright Analytical Centre, The University of New South Wales, Sydney,
NSW 2052, Australia
| | - Maria Kavallaris
- Australian
Centre for NanoMedicine‡Children’s Cancer Institute Australia, Lowy
Cancer Research Centre, §Biomedical Imaging Facility, Mark Wainwright
Analytical Centre, ∥Nuclear Magnetic Resonance Facility, Mark Wainwright Analytical Centre, The University of New South Wales, Sydney,
NSW 2052, Australia
| | - Alexander Macmillan
- Australian
Centre for NanoMedicine‡Children’s Cancer Institute Australia, Lowy
Cancer Research Centre, §Biomedical Imaging Facility, Mark Wainwright
Analytical Centre, ∥Nuclear Magnetic Resonance Facility, Mark Wainwright Analytical Centre, The University of New South Wales, Sydney,
NSW 2052, Australia
| | - Renee Whan
- Australian
Centre for NanoMedicine‡Children’s Cancer Institute Australia, Lowy
Cancer Research Centre, §Biomedical Imaging Facility, Mark Wainwright
Analytical Centre, ∥Nuclear Magnetic Resonance Facility, Mark Wainwright Analytical Centre, The University of New South Wales, Sydney,
NSW 2052, Australia
| | - James Hook
- Australian
Centre for NanoMedicine‡Children’s Cancer Institute Australia, Lowy
Cancer Research Centre, §Biomedical Imaging Facility, Mark Wainwright
Analytical Centre, ∥Nuclear Magnetic Resonance Facility, Mark Wainwright Analytical Centre, The University of New South Wales, Sydney,
NSW 2052, Australia
| | - Thomas P. Davis
- Australian
Centre for NanoMedicine‡Children’s Cancer Institute Australia, Lowy
Cancer Research Centre, §Biomedical Imaging Facility, Mark Wainwright
Analytical Centre, ∥Nuclear Magnetic Resonance Facility, Mark Wainwright Analytical Centre, The University of New South Wales, Sydney,
NSW 2052, Australia
| | - Cyrille Boyer
- Australian
Centre for NanoMedicine‡Children’s Cancer Institute Australia, Lowy
Cancer Research Centre, §Biomedical Imaging Facility, Mark Wainwright
Analytical Centre, ∥Nuclear Magnetic Resonance Facility, Mark Wainwright Analytical Centre, The University of New South Wales, Sydney,
NSW 2052, Australia
| |
Collapse
|
10
|
Steele TWJ, Huang CL, Widjaja E, Boey FYC, Loo JSC, Venkatraman SS. The effect of polyethylene glycol structure on paclitaxel drug release and mechanical properties of PLGA thin films. Acta Biomater 2011; 7:1973-83. [PMID: 21300188 DOI: 10.1016/j.actbio.2011.02.002] [Citation(s) in RCA: 52] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2010] [Revised: 12/21/2010] [Accepted: 02/02/2011] [Indexed: 01/28/2023]
Abstract
Thin films of poly(lactic acid-co-glycolic acid) (PLGA) incorporating paclitaxel typically have slow release rates of paclitaxel of the order of 1 μg day(-1) cm(-2). For implementation as medical devices a range of zero order release rates (i.e. 1-15 μg day(-1) cm(-2)) is desirable for different tissues and pathologies. Eight and 35 kDa molecular weight polyethylene glycol (PEG) was incorporated at 15%, 25% and 50% weight ratios into PLGA containing 10 wt.% paclitaxel. The mechanical properties were assessed for potential use as medical implants and the rates of release of paclitaxel were quantified as per cent release and the more clinically useful rate of release in μg day(-1) cm(-2). Paclitaxel quantitation was correlated with the release of PEG from PLGA, to further understand its role in paclitaxel/PLGA release modulation. PEG release was found to correlate with paclitaxel release and the level of crystallinity of the PEG in the PLGA film, as measured by Raman spectrometry. This supports the concept of using a phase separating, partitioning compound to increase the release rates of hydrophobic drugs such as paclitaxel from PLGA films, where paclitaxel is normally homogeneously distributed/dissolved. Two formulations are promising for medical device thin films, when optimized for tensile strength, elongation, and drug release. For slow rates of paclitaxel release an average of 3.8 μg day(-1) cm(-2) using 15% 35k PEG for >30 days was achieved, while a high rate of drug release of 12 μg day(-1) cm(-2) was maintained using 25% 8 kDa PEG for up to 12 days.
Collapse
Affiliation(s)
- Terry W J Steele
- Nanyang Technological University, Materials and Science Engineering, Division of Materials Technology, Singapore, Singapore
| | | | | | | | | | | |
Collapse
|
11
|
Hribar KC, Lee MH, Lee D, Burdick JA. Enhanced release of small molecules from near-infrared light responsive polymer-nanorod composites. ACS NANO 2011; 5:2948-2956. [PMID: 21384864 DOI: 10.1021/nn103575a] [Citation(s) in RCA: 81] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
Stimuli-responsive materials undergo structural changes in response to an external trigger (i.e., pH, heat, or light). This process has been previously used for a range of applications in biomedicine and microdevices and has recently gained considerable attention in controlled drug release. Here, we use a near-infrared (NIR) light responsive polymer-nanorod composite whose glass transition temperature (T(g)) is in the range of body temperature to control and enhance the release of a small-molecule drug (<800 Da). In addition to increased temperature and resulting changes in molecule diffusion, the photothermal effect (conversion of NIR light to heat) adjusts the composite above the T(g). Specifically, at normal body temperature (T < T(g)), the structure is glassy and release is limited, whereas when T > T(g), the polymer is rubbery and release is enhanced. We applied this heating system to trigger release of the chemotherapeutic drug doxorubicin from both polymer films and microspheres. Multiple cycles of NIR exposure were performed and demonstrated a triggered and stepwise release behavior. Lastly, we tested the microsphere system in vitro, reporting a ∼90% reduction in the activity of T6-17 cells when the release of doxorubicin was triggered from microspheres exposed to NIR light. This overall approach can be used with numerous polymer systems to modulate molecule release toward the development of unique and clinically applicable therapies.
Collapse
Affiliation(s)
- Kolin C Hribar
- Department of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
| | | | | | | |
Collapse
|
12
|
Nagesha DK, Tada DB, Stambaugh CKK, Gultepe E, Jost E, Levy CO, Cormack R, Makrigiorgos GM, Sridhar S. Radiosensitizer-eluting nanocoatings on gold fiducials for biologicalin-situimage-guided radio therapy (BIS-IGRT). Phys Med Biol 2010; 55:6039-52. [DOI: 10.1088/0031-9155/55/20/001] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
13
|
Pharmacokinetics of doxorubicin after intratumoral injection using a thermosensitive hydrogel in tumor-bearing mice. J Control Release 2010; 142:101-7. [DOI: 10.1016/j.jconrel.2009.10.003] [Citation(s) in RCA: 100] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2009] [Revised: 09/07/2009] [Accepted: 10/03/2009] [Indexed: 12/26/2022]
|
14
|
|
15
|
Dong Y, Chin SF, Blanco E, Bey EA, Kabbani W, Xie XJ, Bornmann WG, Boothman DA, Gao J. Intratumoral delivery of beta-lapachone via polymer implants for prostate cancer therapy. Clin Cancer Res 2009; 15:131-9. [PMID: 19118040 DOI: 10.1158/1078-0432.ccr-08-1691] [Citation(s) in RCA: 53] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
PURPOSE beta-Lapachone (ARQ 501, a formulation of beta-lapachone complexed with hydroxypropyl-beta-cyclodextrin) is a novel anticancer agent with selectivity against prostate cancer cells overexpressing the NAD(P)H:quinone oxidoreductase-1 enzyme. Lack of solubility and an efficient drug delivery strategy limits this compound in clinical applications. In this study, we aimed to develop beta-lapachone-containing polymer implants (millirods) for direct implantation into prostate tumors to test the hypothesis that the combination of a tumor-specific anticancer agent with site-specific release of the agent will lead to significant antitumor efficacy. EXPERIMENTAL DESIGN Survival assays in vitro were used to test the killing effect of beta-lapachone in different prostate cancer cells. beta-Lapachone release kinetics from millirods was determined in vitro and in vivo. PC-3 prostate tumor xenografts in athymic nude mice were used for antitumor efficacy studies in vivo. RESULTS beta-Lapachone killed three different prostate cancer cell lines in an NAD(P)H:quinone oxidoreductase-1-dependent manner. Upon incorporation of solid-state inclusion complexes of beta-lapachone with hydroxypropyl-beta-cyclodextrin into poly(D,L-lactide-co-glycolide) millirods, beta-lapachone release kinetics in vivo showed a burst release of approximately 0.5 mg within 12 hours and a subsequently sustained release of the drug ( approximately 0.4 mg/kg/d) comparable with that observed in vitro. Antitumor efficacy studies showed significant tumor growth inhibition by beta-lapachone millirods compared with controls (P < 0.0001; n = 10 per group). Kaplan-Meier survival curves showed that tumor-bearing mice treated with beta-lapachone millirods survived nearly 2-fold longer than controls, without observable systemic toxicity. CONCLUSIONS Intratumoral delivery of beta-lapachone using polymer millirods showed the promising therapeutic potential for human prostate tumors.
Collapse
Affiliation(s)
- Ying Dong
- Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Jia Z, Wong L, Davis TP, Bulmus V. One-pot conversion of RAFT-generated multifunctional block copolymers of HPMA to doxorubicin conjugated acid- and reductant-sensitive crosslinked micelles. Biomacromolecules 2008; 9:3106-13. [PMID: 18844406 DOI: 10.1021/bm800657e] [Citation(s) in RCA: 129] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
N-(2-Hydroxypropyl)methacrylamide (HPMA) containing polymers that are widely used as anticancer drug carriers. We have synthesized new amphiphilic block copolymers of HPMA with a functional monomer 2-(2-pyridyldisulfide)ethylmethacrylate (PDSM) via reversible addition-fragmentation chain transfer (RAFT) polymerization. In a one-pot reaction, the versatility of PDS groups on poly(PDSM)- b-poly(HPMA) was used to conjugate an anticancer drug, doxorubicin (DOX), and also simultaneously crosslink the micellar assemblies via acid-cleavable hydrazone bonds and reducible disulfide bonds. DOX-conjugated crosslinked micelles with an average diameter of approximately 60 nm were observed to be formed in aqueous medium. Disintegration of the micelles into unimers in the presence of a disulfide reducing agent confirmed the crosslinking via disulfide bonds. While the release of DOX from the crosslinked micelles at pH 5.0 was faster compared to the release at pH 7.4, a high proportion of released DOX was found to retain the original active structure. Overall results demonstrate the simplicity and the versatility of the poly(PDSM)- b-poly(HPMA) system, which are potentially important in the design of new generation of polymer therapeutics.
Collapse
Affiliation(s)
- Zhongfan Jia
- Centre for Advanced Macromolecular Design, School of Chemical Sciences and Engineering, The University of New South Wales, Sydney 2052, NSW, Australia
| | | | | | | |
Collapse
|
17
|
Model simulation and experimental validation of intratumoral chemotherapy using multiple polymer implants. Med Biol Eng Comput 2008; 46:1039-49. [PMID: 18523817 DOI: 10.1007/s11517-008-0354-7] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2007] [Accepted: 05/08/2008] [Indexed: 10/22/2022]
Abstract
Radiofrequency ablation has emerged as a minimally invasive option for liver cancer treatment, but local tumor recurrence is common. To eliminate residual tumor cells in the ablated tumor, biodegradable polymer millirods have been designed for local drug (e.g., doxorubicin) delivery. A limitation of this method has been the extent of drug penetration into the tumor (<5 mm), especially in the peripheral tumor rim where thermal ablation is less effective. To provide drug concentration above the therapeutic level as needed throughout a large tumor, implant strategies with multiple millirods were devised using a computational model. This dynamic, 3-D mass balance model of drug distribution in tissue was used to simulate the consequences of various numbers of implants in different locations. Experimental testing of model predictions was performed in a rabbit VX2 carcinoma model. This study demonstrates the value of multiple implants to provide therapeutic drug levels in large ablated tumors.
Collapse
|